In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
Without standardized dosing research, claims about "optimal" dosing are speculative
Noom also offers other plans for guidance and support around GLP-1 medication or hormone replacement therapy (HRT) for menopause
One food monitor did not work for one mouse in vehicle group
There were no increases in pancreatitis or pancreatic cancer noted [11,14]
We need to gather more evidence as a profession and to do that we need more intelligence, we need more complaints," he said